Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Resource Type
Article
Authors
du Bois, Andreas ; Kristensen, Gunnar ; Ray-Coquard, Isabelle ; Reuss, Alexander ; Pignata, Sandro ; Colombo, Nicoletta ; Denison, Ursula ; Vergote, Ignace ; del Campo, Jose M ; Ottevanger, Petronella ; Heubner, Martin ; Minarik, Thomas ; Sevin, Emmanuel ; de Gregorio, Nikolaus ; Bidziński, Mariusz ; Pfisterer, Jacobus ; Malander, Susanne ; Hilpert, Felix ; Mirza, Mansoor R ; Scambia, Giovanni ; Meier, Werner ; Nicoletto, Maria O ; Bjørge, Line ; Lortholary, Alain ; Sailer, Martin Oliver ; Merger, Michael ; Harter, Philipp
Source
In The Lancet Oncology January 2016 17(1):78-89
Subject
Primary Research Articles
Language
ISSN
1470-2045